Drug Profile
EP 7041
Alternative Names: EP-7041; HSK-36273Latest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator eXIthera Pharmaceuticals
- Developer eXIthera Pharmaceuticals; Haisco Pharmaceutical Group
- Class Amides; Amines; Anticoagulants; Antithrombotics; Azetidines; Carboxylic acids; Cycloparaffins; Small molecules
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombosis
Most Recent Events
- 05 Oct 2023 eXIthera Pharmaceuticals withdraws a phase II trial in Thrombosis in USA (IV) (NCT05040776)
- 11 Nov 2022 Haisco Pharmaceutical plans a phase II trial for Blood coagulation disorders in China (IV, Infusion) (NCT05602129)
- 15 Sep 2022 Haisco Pharmaceutical Group completes a phase I trial in Thrombosis (In volunteers) in China (IV) (NCT05742126)